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    INTRODUCTION 
 
Stroke is characterized by the sudden loss of blood circulation to an 
area of the brain, resulting in a corresponding loss of neurologic function. 
Also previously called cerebrovascular accident (CVA) or stroke syndrome, 
stroke is a nonspecific term encompassing a heterogeneous group of 
pathophysiologic causes.54 
 
Broadly, however, strokes are classified as either hemorrhagic or 
ischemic. Acute ischemic stroke refers to stroke caused by thrombosis or 
embolism and is more common than hemorrhagic stroke. (Prior literature 
indicated that only 8-18% of strokes are hemorrhagic, but a retrospective 
review from a stroke center found that 40.9% of 757 strokes included in the 
study were hemorrhagic.  54 
 
The terms intracerebral hemorrhage (ICH) and hemorrhagic stroke 
are used interchangeably in this discussion and are regarded as separate 
entities from hemorrhagic transformation of ischemic stroke. Intracerebral 
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hemorrhage accounts for 10-15% of all strokes and is associated with 
higher mortality rates than cerebral infarctions. 54 
Patients with hemorrhagic stroke present with similar focal neurologic 
deficits but tend to be more ill than patients with ischemic stroke. Patients 
with intracerebral bleeds are more likely to have headache, altered mental 
status, seizures, nausea and vomiting, and/or marked hypertension; 
however, none of these findings reliably distinguishes between 
hemorrhagic stroke and ischemic stroke. Though stroke is less common in 
children, the clinical presentation is similar. 54 
 
Stroke is one of the leading causes of mortality and morbidity in India. 
Community surveys have shown a crude prevalence rate for hemiplegia in 
the range of 200 per 1,00,000 persons, nearly 1.5% of all urban hospital 
admissions, 4.5% of all medical and around 20% neurological cases. 
 
The association between cholesterol and stroke remain uncertain. 
Epidemiological studies have failed to associate cerebral infarction and 
cholesterol, but they have found an inverse relation with the incidence of 
intracerebral hemorrhage (ICH).1,6 
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  SPARCL study suggests that statins increase the occurrence of ICH, 
which enhances the controversy.2 Moreover, an association between low 
cholesterol and mortality attribuable to ICH has been documented in 
several large population-based studies.3,4 Additionally, higher cholesterol 
levels have been associated with better short-term health outcome after 
stroke, including ICH.5,7 
 
Hemorrhagic transformation (HTf) frequently complicates ischemic 
stroke with or without thrombolytic treatment. HTf after acute ischemic 
stroke is known to associate with poor outcome and delays the initiation of 
proper anticoagulation treatment for stroke with cardioembolism (CE). HTf 
occurs after extravasation of blood over damaged cerebral vascular 
endothelium in acute ischemic stroke.  
 
Similar to the association of low LDL-C with incidence of hemorrhagic 
stroke, there should be an association of low LDL-C cholesterol with 
incidence of hemorrhagic transformation in ischemic stroke. 
This study is intended to substantiate or disprove the associations 
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AIMS AND OBJECTIVES 
 
1. To classify stroke patients in to acute hemorrhagic stroke and acute 
large artery thrombotic stroke. 
 
2. To exclude the patients with recurrent stroke or patients taking 
antilipidemic drugs. 
 
 
3. To measure Lipid Profile including LDL-cholesterol for the above 
patients. 
 
4. To find the association of LDL-cholesterol levels and some other 
parameters with the 30 day mortality in hemorrhagic stroke patients. 
 
 
5. To find the association of LDL-cholesterol levels and few other 
parameters with the incidence of hemorrhagic transformation in large 
artery thrombotic stroke patients. 
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REVIEW OF LITERATURE 
 
HEMORRHAGIC STROKE 
 
The etiologies of stroke are varied, but they can be broadly 
categorized into ischemic or hemorrhagic infarctions. Approximately 80-
87% of strokes are from ischemic infarction due to thrombotic or embolic 
cerebrovascular occlusion. Hemorrhagic infarctions comprise most of the 
remainder of strokes, with a smaller number due to aneurysmal 
subarachnoid hemorrhage. Furthermore, 20-40% of patients with ischemic 
infarction may develop hemorrhagic transformation within 1 week after 
ictus. Intracerebral hemorrhage accounts for 10-15% of all strokes and is 
associated with higher mortality rates than cerebral infarctions. 54 
 
CAUSES: 54 
• Cerebral amyloidosis (affects people who are elderly and may cause up to 
10% of intracerebral hemorrhages) 
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• Coagulopathies (eg, due to underlying systemic disorders such as 
bleeding diathesis or liver disease) 
• Anticoagulant therapy 
• Thrombolytic therapy for acute myocardial infarction (MI) and acute 
ischemic stroke (can cause iatrogenic hemorrhagic transformation) 
• Arteriovenous malformation 
• Intracranial aneurysm 
• Vasculitis 
• Intracranial neoplasm 
 
 
The risk of stroke is increased with the following factors: 
• Advanced age 
• Hypertension (up to 60% of cases) 
• Previous history of stroke 
• Alcohol and illicit drug use, such as cocaine and other sympathomimetic 
drugs 
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CLINICAL FEATURES: 
 
Generalized symptoms, including nausea, vomiting, and headache as 
well as an altered level of consciousness may indicate increased 
intracranial pressure and are more common with hemorrhagic strokes or 
large ischemic strokes. Seizures are more common in hemorrhagic stroke 
than in ischemic stroke and occur in up to 28% of hemorrhagic strokes, 
generally at the onset of the intracerebral hemorrhage or within the first 24 
hours. 55 
 
Other, more focal, symptoms of stroke include weakness or paresis 
that may affect a single extremity, one half of the body, or all 4 extremities; 
facial droop; monocular or binocular blindness; blurred vision or visual field 
deficits; dysarthria and trouble understanding speech; vertigo or ataxia; and 
aphasia. The neurologic deficits reflect the area of the brain typically 
involved, and stroke syndromes for specific vascular lesions have been 
described. 55 
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Intracerebral hemorrhage may be clinically indistinguishable from 
ischemic stroke. Hypertension is commonly a prominent finding. An acute 
onset of neurologic deficit, altered level of consciousness/mental status, or 
coma is more common with hemorrhagic stroke than with ischemic stroke. 
Often, this is due to an increase in intracranial pressure. Meningismus may 
result from blood in the ventricles. 55 
 
Specific brain sites and deficits involved in hemorrhagic stroke include the 
following: 55 
 
• Putamen - Contralateral hemiparesis, contralateral sensory loss, 
contralateral conjugate gaze paresis, homonymous hemianopia, aphasia, 
neglect, or apraxia 
 
• Thalamus - Contralateral sensory loss, contralateral hemiparesis, gaze 
paresis, homonymous hemianopia, miosis, aphasia, or confusion 
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• Lobar - Contralateral hemiparesis or sensory loss, contralateral conjugate 
gaze paresis, homonymous hemianopia, abulia, aphasia, neglect, or 
apraxia 
 
• Caudate nucleus - Contralateral hemiparesis, contralateral conjugate 
gaze paresis, or confusion 
 
 
• Brainstem - Quadriparesis, facial weakness, decreased level of 
consciousness, gaze paresis, ocular bobbing, miosis, or autonomic 
instability 
 
• Cerebellum - Ataxia (usually beginning in the trunk), ipsilateral facial 
weakness, ipsilateral sensory loss, gaze paresis, skew deviation, miosis, 
or decreased level of consciousness 
 
 
Other signs of cerebellar or brainstem involvement include the following: 55 
• Gait or limb ataxia 
• Vertigo or tinnitus 
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• Nausea and vomiting 
• Hemiparesis or quadriparesis 
• Hemisensory loss or sensory loss of all 4 limbs 
• Eye movement abnormalities resulting in diplopia or nystagmus 
• Oropharyngeal weakness or dysphagia 
• Crossed signs (ipsilateral face and contralateral body) 
Many other stroke syndromes are associated with intracerebral 
hemorrhage and range from mild headache to neurologic devastation. At 
times, a cerebral hemorrhage may present as a new-onset seizure. 
 
WORKUP: 
Brain imaging is a crucial step in a patient's evaluation and must be 
obtained on an emergent basis. Brain imaging aids in making the diagnosis 
of hemorrhage, and it may identify complications such as intraventricular 
hemorrhage, brain edema, or hydrocephalus. Either NCCT scanning or 
magnetic resonance imaging (MRI) of the brain is the modality of choice. 56 
 
Imaging has greatly evolved in the past 2 decades, and advanced CT 
and magnetic resonance neuroimaging techniques have been developed 
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for improved physiologic imaging of acute stroke. These techniques allow 
clinicians to assess for the core infarct size and to characterize cerebral 
blood volume and cerebral blood flow to identify potentially salvageable 
tissue at risk for infarction (ie, ischemic penumbra). Some examples of 
these techniques include diffusion-weighted MRI (DWI) and perfusion 
imaging of acute stroke with magnetic resonance and CT scanning. 56 
CT scanning and magnetic resonance angiography (MRA) can give 
useful information regarding large-vessel occlusion, which is an important 
consideration, as intraarterial interventions for acute ischemic stroke are 
available. Although the sensitivity of CT scanning and MRI for large-vessel 
occlusion is conceivably similar, CT angiography (CTA) may be more 
practical for several reasons. For example, its more rapid image acquisition 
makes CTA less susceptible to motion artifacts, more accurate at depicting 
vascular anatomy, and more sensitive for stenosis, occlusion, vascular 
malformations, and aneurysms. 56 
 
Imaging with CT studies has multiple logistic advantages for patients 
with acute stroke; it is able to more rapidly acquire images than magnetic 
resonance studies, allowing for assessment with an examination that 
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includes NCCT, CTA, and CT perfusion in less than 10 minutes. Expedient 
acquisition is of the utmost importance in acute stroke imaging because of 
the narrow window of time available for definitive ischemic stroke treatment 
with pharmacologic agents and mechanical devices. CT studies can also 
be performed in patients who are unable to tolerate a magnetic resonance 
examination or who have contraindications to MRI, including pacemakers, 
aneurysm clips, or other ferromagnetic materials in their bodies. 
Additionally, CT examination is more easily accessible for patients who 
require special equipment for maintaining and monitoring life support. 56 
 
Ultrasonography has multiple uses in the workup of stroke patients. 
This examination is usually performed on a nonemergent basis to evaluate 
cerebrovascular ischemic disease preoperatively or in the acute setting 
after evaluation with CT scanning or MRI. 56 
 
Transthoracic and transesophageal echocardiography (TTE and TEE, 
respectively) may also be used in assessing for cardioembolic disease and 
patent foramen ovale or, more acutely, to exclude thoracic aortic 
dissection. 56 
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Conventional angiography is the gold standard in evaluating for 
cerebrovascular disease, as well as for disease involving the aortic arch 
and great vessels in the neck, and for providing less invasive endovascular 
interventions. This modality can be performed to clarify equivocal findings 
or to confirm and treat disease seen on MRA, CTA, transcranial Doppler, or 
neck ultrasonograms. 56 
 
Angiography is also useful in preoperative evaluation for 
hemodynamically significant or flow limiting lesions and to confirm the 
presence of trickle flow versus occlusion seen on ultrasonography when 
considering carotid endarterectomy. Angiography is also more sensitive 
than MRA for detecting ulceration and is superior to both MRA and CTA for 
detecting vasculitis. Angiography allows for endovascular treatment with 
intraarterial thrombolytic therapy or mechanical thrombectomy in acute 
stroke and for stenting of patients with arterial stenosis intracranially or in 
the neck. It can also be used to characterize and treat aneurysms and 
vascular malformations using stents and embolic agents, such as coils or 
other embolic material. 56 
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MANAGEMENT: 
Medications used in the treatment of acute stroke include 
anticonvulsants to prevent seizure recurrence, antihypertensive agents to 
reduce BP and other risk factors of heart disease, and osmotic diuretics to 
decrease intracranial pressure in the subarachnoid space. 57 
Perform endotracheal intubation for patients with a decreased level of 
consciousness and poor airway protection. Intubate and hyperventilate if 
intracranial pressure is increased, and initiate administration of mannitol for 
further control. Rapidly stabilize vital signs, and simultaneously acquire 
emergent CT scan. 57 
 
Management of seizures: 
 
Early seizure activity occurs in 4-28% of patients with intracerebral 
hemorrhage, and these seizures are often nonconvulsive seizures.[23, 
21]Seizure activity should be rapidly controlled with a benzodiazepine, such 
as lorazepam or diazepam, accompanied by either phenytoin or 
fosphenytoin loading. Prophylactic anticonvulsant therapy is recommended 
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in patients with lobar hemorrhages to reduce the risk of early seizures.[1, 
23] However, the use of prophylactic anticonvulsant therapy in all cases of 
intracerebral hemorrhage is controversial, as no prospective controlled 
trials have demonstrated a clear benefit. 57 
 
According to the AHA/ASA 2010 guidelines for management of 
spontaneous ICH, patients with a change in mental status and whose EEG 
shows electrographic seizures should receive antiepileptic drugs.57 
 
Blood pressure control: 
 
No controlled studies define optimum BP levels, but greatly elevated 
BP is thought to lead to rebleeding and hematoma expansion. Patients who 
have had a stroke may lose their cerebral autoregulation of cerebral 
perfusion pressure. Rapid or aggressive BP lowering may compromise 
cerebral perfusion. Nicardipine, labetalol, esmolol, and hydralazine are 
agents that may be used when necessary for BP control. Avoid 
nitroprusside because it may raise intracranial pressure. 57 
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The American Heart Association guidelines for treating elevated BP are as 
follows : 
• If systolic BP is >200 mm Hg or mean arterial pressure (MAP) is >150 mm 
Hg, then consider aggressive reduction of BP with continuous IV infusion 
with frequent BP (every 5 min) checks. 
• If systolic BP is >180 mm Hg or MAP is >130 mm Hg and there is 
evidence or suspicion of elevated intracranial pressure, then consider 
monitoring of intracranial pressure and reducing BP using intermittent or 
continuous IV medications to maintain cerebral perfusion pressure >60-80 
mm Hg. 
 
• If systolic BP is >180 or MAP is >130 mm Hg and there is NOT evidence 
or suspicion of elevated intracranial pressure, then consider modest 
reduction of BP (target MAP of 110 mm Hg or target BP of 160/90 mm 
Hg) with BP checks every 15 minutes. 
 
 
One prospective study found a hazard ratio of 1.89 for the risk of poor 
outcome for each 10% decrease in systolic BP in the first 24 hours of an 
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acute stroke. Another study found that the use of calcium channel blockers 
acutely lowered diastolic BP and was associated with worse outcomes57  
 
Current recommendations include avoiding more than 10% reduction 
of BP within the first 24 hours, unless values exceed certain thresholds. 
These values, which are not based on any specific randomized studies, are 
220 mm Hg systolic (some recommend 200 mm Hg systolic) and 115 mm 
Hg diastolic. Suggested agents for use in the acute setting are beta-
blockers (eg, labetalol) and angiotensin-converting enzyme inhibitors 
(ACEIs) (eg, enalapril). For more refractory hypertension, agents such as 
nicardipine, nitroprusside, and hydralazine are used. 57 
 
Medical treatment of increased intracranial pressure: 
 
Elevated intracranial pressure may result from the hematoma itself, 
surrounding edema, or both. The frequency of increased intracranial 
pressure in patients with intracerebral hemorrhage is not known. 57 
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Elevate the head of the bed to 30 degrees. This improves jugular 
venous outflow and lowers intracranial pressure. The head should be 
midline and not turned to the side. Provide analgesia and sedation as 
needed. 57 
 
More aggressive therapies such as osmotic therapy (mannitol, 
hypertonic saline), barbiturate anesthesia, and neuromuscular blockage 
generally require concomitant monitoring of intracranial pressure and BP 
with an intracranial pressure monitor to maintain adequate cerebral 
perfusion pressure (CPP) greater than 70 mm Hg. A randomized controlled 
study of mannitol in intracerebral hemorrhage failed to demonstrate any 
difference in disability or death at 3 months. 57 
 
Hyperventilation (partial pressure of carbon dioxide [PaCO2] of 25 to 
30-35 mm Hg) is not recommended, because its effect is transient, it 
decreases CBF, and it may result in rebound elevated intracranial 
pressure.[1]Glucocorticoids are not effective and result in higher rates of 
complications with poorer outcomes. 57 
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Surgical Intervention 
 
Craniotomy and evacuation: 
One of the modalities of treatment is craniotomy and surgical 
evacuation of hematoma. The role of surgical treatment for supratentorial 
intracranial hemorrhage remains controversial. Outcomes in published 
studies are conflicting. A published meta-analysis of studies suggested 
some promise for early surgical intervention. However, one study 
comparing early surgery versus initial conservative treatment failed to 
demonstrate a benefit with surgery. 57 
 
Surgical intervention for cerebellar hematoma has been shown to 
improve outcome. It can be lifesaving in the prevention of brainstem 
compression. 
 
Endovascular treatment of aneurysms: 
Endovascular treatment of aneurysms using coils has been 
increasingly used in recent years with great success as an alternative to 
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surgical clipping (see the following images), although controversy still exists 
over which treatment is ultimately superior. 57 
 
 
 
ACUTE ISCHEMIC STROKES: 
 
Acute ischemic strokes are the result of vascular occlusion secondary 
to thromboembolic disease. Ischemia results in cell hypoxia and depletion 
of cellular adenosine triphosphate (ATP). Without ATP, energy failure 
results in an inability to maintain ionic gradients across the cell membrane 
and cell depolarization. With an influx of sodium and calcium ions and 
passive inflow of water into the cell, cytotoxic edema results.49 
 
Etiology: 
 
Ischemic strokes result from events that limit or stop blood flow, such 
as extracranial or intracranial thrombosis embolism, thrombosis in situ, or 
relative hypoperfusion. As blood flow decreases, neurons cease 
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functioning, and irreversible neuronal ischemia and injury begin at blood 
flow rates of less than 18 mL/100 g of tissue/min.49 
 
 
 
Risk factors: 
Risk factors for ischemic stroke include modifiable and nonmodifiable 
etiologies. Identification of risk factors in each patient can uncover clues to 
the cause of the stroke and the most appropriate treatment and secondary 
prevention plan.49 
 
Nonmodifiable risk factors include the following: 
• Age 
• Race 
• Sex 
• Ethnicity 
• History of migraine headaches 
• Sickle cell disease 
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• Fibromuscular dysplasia 
• Heredity 
 
Modifiable risk factors include the following: 
• Hypertension (the most important) 
• Diabetes mellitus 
• Cardiac disease - Atrial fibrillation, valvular disease, mitral stenosis, and 
structural anomalies allowing right to left shunting, such as a patent 
foramen ovale and atrial and ventricular enlargement 
• Hypercholesterolemia 
• Transient ischemic attacks (TIAs) 
• Carotid stenosis 
• Hyperhomocystinemia 
• Lifestyle issues - Excessive alcohol intake, tobacco use, illicit drug use, 
obesity, physical inactivity 
• Oral contraceptive use 
 
Among the types of cardiac disease that increase stroke risk are atrial 
fibrillation, valvular disease, mitral stenosis, and structural anomalies 
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allowing right-to-left shunting, such as a patent foramen ovale and atrial 
and ventricular enlargement. 
 
Large-artery occlusion:  
 
Large artery occlusion typically results from embolisation of 
atherosclerotic debris originating from the common or internal carotid 
arteries or from a cardiac source. A smaller number of large-artery 
occlusions may arise from plaque ulceration and in situ thrombosis. Large-
vessel ischemic strokes more commonly affect the MCA territory with the 
ACA territory affected to a lesser degree.49 
 
Investigations: 
Laboratory evaluation of the patient with ischemic stroke should be 
driven by comorbid illnesses as well as the potential acute stroke. 
Additional laboratory tests are tailored to the individual patient. They may 
include rapid plasma reagent (RPR), toxicology screen, fasting lipid profile, 
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sedimentation rate, pregnancy test, antinuclear antibody (ANA), rheumatoid 
factor, and homocysteine.51 
 
CT is the most commonly used form of neuroimaging in the acute 
evaluation of patients with apparent acute stroke. MRI with magnetic 
resonance angiography (MRA) has been a major advance in the 
neuroimaging of stroke; MRI not only provides great structural detail but 
also can demonstrate impaired metabolism. 51 
 
Carotid duplex scanning is one of the most useful tests in evaluating 
patients with stroke. Increasingly, it is being performed earlier in the 
evaluation, not only to define the cause of the stroke but also to stratify 
patients for either medical management or carotid intervention if they have 
carotid stenoses. 51 
 
Digital subtraction angiography is considered the definitive method for 
demonstrating vascular lesions, including occlusions, stenoses, 
dissections, and aneurysms51 
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CBC count serves as a baseline study and may reveal a cause for 
the stroke (eg, polycythemia, thrombocytosis, thrombocytopenia, leukemia) 
or provide evidence of concurrent illness (eg, anemia). 51 
Chemistry panel serves as a baseline study and may reveal a stroke 
mimic (eg, hypoglycemia, hyponatremia) or provide evidence of concurrent 
illness (eg, diabetes, renal insufficiency). 51 
 
Coagulation studies may reveal a coagulopathy and are useful when 
thrombolytics or anticoagulants are to be used. In patients who are not 
anticoagulated and in whom there is no suspicion for coagulation 
abnormality, administration of recombinant tissue-type plasminogen 
activator (rt-PA) should not be delayed awaiting laboratory studies. 51 
 
Cardiac biomarkers are important because of the association of 
cerebral vascular disease and coronary artery disease. Additionally, 
several studies have indicated a link between elevations of cardiac enzyme 
levels and poor outcome in ischemic stroke51 
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Hemorrhagic Transformation of ischemic stroke: 
Hemorrhagic transformation represents the conversion of a bland 
infarction into an area of hemorrhage. Proposed mechanisms for 
hemorrhagic transformation include reperfusion of ischemically injured 
tissue, either from recanalization of an occluded vessel or from collateral 
blood supply to the ischemic territory or disruption of the blood-brain 
barrier. With disruption of the blood-brain barrier, red blood cells 
extravasate from the weakened capillary bed, producing petechial 
hemorrhage or more frank intraparenchymal hematoma.53 
 
Hemorrhagic transformation of an ischemic infarct occurs within 2-14 
days post ictus, usually within the first week. It is more commonly seen 
following cardioembolic strokes and is more likely with larger infarct 
size.Hemorrhagic transformation is also more likely following administration 
of tissue plasminogen activator (tPA) and with noncontrast CT scans 
demonstrating areas of hypodensity.53 
 
There has been a long-standing dispute over the increased risk of 
cerebral hemorrhage at lower levels of cholesterol. Various reports21,30,31 
32 
 
stated that low cholesterol level was associated with cerebral hemorrhage, 
but others32,33 reported against the positive association of low cholesterol 
level and hemorrhagic stroke. Whereas the initial lipid-lowering therapy 
trial34 reported the absence of significant association, recent intensive lipid-
lowering treatment trial23 showed a 68% increase of hemorrhagic stroke by 
treating with 80-mg atorvastatin. 
 
The underlying biological explanation over the mechanism of 
increased cerebral hemorrhages at low levels of TC or LDLC is not yet 
established. There has been reports that adequate cholesterol may be 
important for maintaining the integrity of cerebral small vessels,22,35 and 
that experimental injection of immunoliposome may ameliorate the 
endothelial damage after thrombolysis.36 Additionally, cerebral microbleeds, 
which may reflect the blood extravasation around cerebral small vessels,37 
were known to be prevalent in ischemic stroke patients with low TC 
levels.38  
 
Finally, the low TC or LDLC levels without lipid-lowering therapy may 
reflect poor general medical condition, which is indicative of increased HTf 
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after ischemic stroke. 39 From these considerations, low levels of TC and 
LDLC may increase the incidence of cerebral hemorrhage by way of 
disturbed cerebral small vessel integrity. 
 
These findings lead to the question of under what circumstances 
does HTf occur. Blood–brain barrier consists of endothelial cells of cerebral 
microvessels and the basement membrane and protects the brain against 
noxious chemicals, variations in blood composition, and breakdown of the 
concentration gradient.40 HTf is linked to the processes that alter the 
integrity of the neurovascular unit, which consists of BBB, astrocytes, and 
adjacent neurons,15 and that causes the extravasation of blood over 
ischemic vascular endothelial cells. After ischemic insult, the permeability 
of BBB increases significantly,41 resulting in the extravasation of plasma 
components and edema formation.42  
 
Moreover, not only the vascular endothelial cells but also the 
astroglial cells are known to protect against the increasing permeability 
after hypoxic insult.43 Therefore, after long-standing subclinical hypoxic 
injury to the brain, it is possible that the cumulative damage on endothelial 
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cells, astroglia, and neurons, ie, the neurovascular unit, may evoke HTf 
after acute ischemic stroke. 
 
One of the most important points distinguishing LAA from CE is the 
stenosis of proximal cerebral large arteries. The stenosed proximal arteries 
may damage cerebral neurovascular units of relevant territory in various 
ways. The narrow proximal larger arteries are known to associate with low 
perfusion state in the brain,44 and microemboli are reported to increase in 
stenosis of proximal arteries.45  
 
In contrast, CE, by definition, implies heart-originating embolism 
without meaningful cerebral arterial stenosis,25 and may have relatively 
intact neurovascular unit without long-standing subclinical injuries. In other 
words, HTf may tend to occur in the cerebral vessels of LAA patients who 
have been exposed to various injuries associated with proximal arterial 
stenosis in the hemorrhage-prone condition of low TC or low LDLC. 
However, in the cerebral vessels of CE, which contain relatively intact 
neurovascular unit than those of LAA, low levels of TC or LDLC may have 
limited influence on the occurrence of HTf. 
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MATERIALS AND METHODS  
  
Setting   :   In-patients department,  
                  Institute of Internal Medicine,  
                  Rajiv Gandhi Government General Hospital,                                        
                  Madras Medical College, Chennai.  
  
  
Ethical committee  Approval   :   Obtained   
Design of study  :    Cross sectional study 
Period of study  :     April2011 to November2011.  
Sample size    :         100 patients.  
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Materials & Methods : 
 
Inclusion Criteria: 
 All new onset Acute ischemic stroke of atherothrombotic etiology, 
and Acute intracerebral hemorrhage 
 
Exclusion criteria: 
The following patients were excluded from the study group: 
1. Patients having Embolic stroke 
2. Patients having Recurrent stroke 
3. Patients with Small vessel disease 
4. Stroke of other known etiologies 
5. Stroke of unknown etiologies 
6. Transient ischemic attacks 
7. Patients requiring neurosurgical procedures 
8. Patients already taking antilipidemic drugs 
9. Patients thrombolysed and developing hemorrhagic 
transformation 
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10. Patients with bleeding diathesis or drug induced bleeding 
 
 
 
Methodology & Investigation details for ICH patients: 
 
Intracerebral hemorrhage patients admitted to our hospital, other than 
those  coming under exclusion criteria are taken up. The history of 
diabetes, systemic hypertension, antilipidemic drug intake and smoking 
and alcohol history, all are recorded. Their vitals, GCS are recorded. 
Lipid profile including LDL-C, HDL-C, Total C, Triglycerides all are done 
and recorded. ICH site, and volume are noted down. Volume <40ml is 
considered as mild; 40-60ml moderate and >60ml is considered severe. 
 
The patients are followed up over a period of one month and the 
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mortality related to ICH per se is noted down. Then the patients are 
segregated into two groups: patients who died and patients who 
survived. The two study groups are compared according to their mean 
and standard deviation for lipid profile and BP. Any statistically 
significant difference is noted down. 
Methodology and investigation details for thrombotic stroke: 
All thrombotic infarct patients with occlusion of large arteries like  
Proximal MCA, PCA are taken into account. History of smoking, 
Alcoholism, diabetes, systemic hypertension, drug intake and previous 
history of stroke are recorded. With the exclusion criteria, some of the 
patients are excluded. Basic investigations like Blood sugar, Lipid profile 
are taken. Admission BP and GCS are noted down.  
All patients have to undergo a repeat CT preferably at one week 
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interval to look for hemorrhagic transformation. The data is analysed by 
grouping the patients into two groups – those with and without 
hemorrhagic transformation.  
DATA ANALYSIS: 
 After collection, the data is segregated in to various groups and 
analysed using unpaired t test and chi square test. P values are 
calculated and the statistical significance interpreted. 
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 RESULTS 
INTRACEREBRAL HEMORRHAGE PATIENTS 
Patient characteristics for ICH: 
Patient character Percentage or median with quartiles 
AGE: 
                    <40yrs 
                    40 – 50 yrs 
                    50 - 60yrs 
                    60 – 70yrs 
                    >70yrs 
 
2% 
28% 
34% 
22% 
14% 
Males 70% 
Females 30% 
H/O diabetes 36% 
H/O systemic hypertension 46% 
H/O smoking 46% 
H/O alcoholism 36% 
 
 
Patient profile after admission: 
Parameter Percentage  
BP: 
Systolic: 
                                   ≤140mmHg 
                                   140-160mmHg 
                                   >160mmHg 
Diastolic: 
                                   ≤90mmHg 
                                   90 – 100mmHg 
 
 
12% 
20% 
68% 
12% 
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                                   >100mmHg 20% 
68% 
Total cholesterol 
                                   150 – 200 
                                   ≥200 
 
78% 
22% 
Triglycerides  
                                   ≤150 
                                   150 – 199 
                                   ≥200 
 
22% 
54% 
24% 
HDL 
                                   <40 
                                   ≥40 
 
34% 
66% 
LDL – cholesterol 
                                   <100 
                                   100 – 110 
                                   >110 
 
30% 
20% 
50% 
ICH site 
              Gangliocapsular, thalamic 
              Lobar 
 
60% 
40% 
ICH volume 
                         Mild 
                         Moderate  
                         Massive  
 
24% 
40% 
36% 
GCS 
                         >10 
                         6 – 10 
                         < 6 
 
16% 
42% 
42% 
90 day mortality 52% 
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Comparison of died and survived patients in 30 days: 
Parameter  Among died 
patients 
26pts 
Among 
survived 
patients 
24pts 
LDL-C 
           <100 
              100 – 110 
            >110 
 
42% 
23% 
35% 
 
17% 
17% 
66% 
Total cholesterol 
             150 – 199 
             ≥200 
 
77% 
23% 
 
79% 
21% 
Triglycerides 
            <150 
            150 – 200 
            >200 
 
23% 
62% 
15% 
 
17% 
54% 
29% 
BP on admission: 
             <160/100 
             >160/100 
 
19% 
81% 
 
29% 
71% 
Lobar 46% 29% 
Gangliocapsular 
and thalamic  
54% 71% 
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34%
22%
50 - 60yrs 60 - 70yrs >70yrs
Age distribution
70%
 
14%
MALES
FEMALES
 LDL-Cholesterol among survived and died patients
 
Total Cholesterol among died and survived patients
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100 – 110 >110
23%
35%
17%
66%
Died patients Survived patients
>200
23%
79%
21%
Died Survived
 
 
 Triglycerides among died and survived 
 
 
Comparison of Admission BP among died and survived patients:
0%
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100%
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54%
29%
Died Survived
>160/100
19%
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Died survived
 
 
 Site of Hemorrhage and survival rate:
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LARGE ARTERY THROMBOTIC INFFARCT PATIENTS 
Patient character Percentage or median with quartiles 
AGE: 
                    <40yrs 
                    40 – 50 yrs 
                    50 - 60yrs 
                    60 – 70yrs 
                    >70yrs 
 
6% 
16% 
42% 
26% 
10% 
Males 68% 
Females 32% 
H/O diabetes 50% 
H/O systemic hypertension 48% 
H/O smoking 40% 
H/O alcoholism 36% 
 
Patient profile after admission: 
Parameter Percentage  
BP: 
Systolic: 
                                   ≤140mmHg 
                                   140-160mmHg 
                                   >160mmHg 
Diastolic: 
                                   ≤90mmHg 
                                   90 – 100mmHg 
                                   >100mmHg 
 
 
14% 
42% 
44% 
32% 
32% 
36% 
Total cholesterol 
                                   150 – 200 
                                   ≥200 
 
82% 
18% 
Triglycerides  
                                   ≤150 
                                   150 – 199 
                                   ≥200 
 
14% 
64% 
22% 
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HDL 
                                   <40 
                                   ≥40 
 
42% 
58% 
LDL – cholesterol 
                                   <100 
                                   100 – 110 
                                   >110 
 
28% 
32% 
40% 
Infarct territory 
              ACA 
              MCA 
              PCA 
 
2% 
82% 
16% 
GCS 
                         >10 
                         6 – 10 
                         < 6 
 
6% 
76% 
18% 
Hemorrhagic transformation 28% 
 
Comparison of patients with and without hemorrhagic transformations: 
Parameter  Among patients with Hgic 
transformation 14pts 
Among patients without 
Hgic transformation 36pts 
LDL-C 
           <100 
              100 – 110 
            >110 
 
57% 
14% 
29% 
 
17% 
39% 
44% 
Total cholesterol 
             150 – 199 
             ≥200 
 
86% 
14% 
 
81% 
19% 
Triglycerides 
             <150 
             150-200 
             >200 
 
0% 
71% 
29% 
 
8% 
73% 
19% 
BP on admission: 
             <160/100 
             >160/100 
 
50% 
50% 
 
36% 
64% 
MCA teritorry 86% 83% 
PCA teritorry 14% 17% 
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71%
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DISCUSSION 
 
Mortality in ICH: 
 
Parameter Mean ± SD for 
Died patients 
n=26 
Mean ± SD for 
Survived pts 
N=24 
P value 
LDL - C 108 ± 24 116 ± 17 0.1697 (ns) 
Total C 180 ± 23 191 ± 18 0.0538 (ss) 
TGL 168 ± 30 181 ± 27 0.1031 (ns) 
HDL 40 ± 5 40 ± 5 0.7981 (ns) 
Systolic BP 171 ± 37 169 ± 20 0.8556 (ns) 
Diastolic BP 110 ± 22 114 ± 13 0.4256 (ns) 
 
According to the above statistics, the mean LDL-C of patients with 
ICH who died was 108 with a standard deviation of 24; Where as 
it was 116 with a standard deviation of 17. Though the levels of 
LDL-C is little lower in patients who died, the p value is 0.1697 
which implies that this is not statistically significant. This 
contradicts the study conducted by Jose Maria et al, who proved 
that lower LDL-C predicts ICH mortality. 
53 
 
The mean total cholesterol of patients who died was 180 with a 
SD of 23; for patients who survived it was 191 with a SD of 18. 
This data carries a P value of 0.0538 and is not of much 
significance statistically. But we can imply that a lower total 
cholesterol can predict mortality to some extent. Studies have a 
revealed a U shaped relationship between total cholesterol and all 
cause mortality.8 
 
The mean triglycerides of patients who died was 168 with a SD of 
30, and of patients  who survived was 181 with a SD of 27; The P 
value was 0.1031; Again though this is not statistically significant, 
we can infer that to some extent lower triglyceride levels similar to 
total cholesterol levels, can predict mortality to some extent. 
 
The HDL levels of both the study groups were almost same and 
no significant value could be obtained  
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Similary the systolic and diastolic BP are also of the same among 
both the study groups and no significant difference obtained. 
. 
Some authors suggest that higher cholesterol levels are 
associated with lesser hemorrhage growth.9 Cholesterol is known 
to have effects on the vasculature and is essential for normal 
membrane fluidity, and adequate cholesterol levels may be 
important for maintaining the integrity of vessels and their 
resistance to rupture.10 
Theoretically, statins may increase the risk of cerebral 
hemorrhage because high cholesterol apparently protects 
against ICH.2 Meta-analyses provide evidence that the statins 
significantly reduce the risk of ischemic stroke, however a 
recent review suggests that this beneficial effect is partly 
reduced by increasing ICH.11 
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Other predictors of mortality in ICH: 
 
AGE vs MORTALITY     [P = 0.4720] not significant 
 
PATIENTS AGE <40 40-50 50-60 60-70 >70 
DIED 1 7 5 8 5 
SURVIVED 0 7 12 3 2 
 
ICH incidence is highest in the age group 50 – 60yrs. But the 
mortality seems to be highest in older age groups. But the p valus 
is higher and this is not statistically significant 
SEX vs MORTALITY    [P = 0.9318] not significant 
 
PATIENTS MALES FEMALES 
DIED 18 8 
SURVIVED 17 7 
 
Incidence of ICH is more among males. But the mortality seems 
to be that of same incidence in both sexes. P value is much 
higher and the test is not statistically significant 
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ICH VOLUME vs MORTALITY     [P = 0.0006] very much 
significant 
 
PATIENTS ICH VOLUME 
     <40ml 
ICH VOLUME 
       40 – 60ml 
ICH VOLUME 
       >60ml 
DIED 0 8 18 
SURVIVED 12 12 0 
 
When the ICH volume goes more than 60ml, all patients in our 
study invariably died. This test carries a p value of 0.0006 and is 
very much statistically significant. 
 
ICH SITE vs MORTALITY     [P = 0.2319]  not significant 
 
PATIENTS GANGLIOCAPSULAR THALAMIC LOBAR 
DIED 14 0 12 
SURVIVED 11 5 8 
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Gangliocapsular hemorrhage is more commoner than lobar. But 
mortality is almost equal among both groups. None of the 
thalamic hemorrhage patients died. But that is because the 
volume of hemorrhage is very less. The test carries a P value of 
0.2319 and not of statistically significant. 
 
From the above data, it is clear that mortality is significantly 
related to the ICH volume and not much significantly related to the 
other parameters like age, sex, and site of ICH 
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Hemorrhagic Transformation in Large Artery Infarct: 
 
Parameter Mean ± SD for 
pts with HgT 
n = 15 
Mean ± SD for 
Pts without 
HgT 
N = 35 
P value 
LDL - C 100 ± 15 113 ± 17 0.015 (ss) 
Total C 177 ± 17 188 ± 17 0.0345 (ss) 
TGL 181 ± 22 179 ± 23 0.7654 (ns) 
HDL 41 ± 7 40 ± 5 0.5789 (ns) 
Systolic BP 165 ± 16 161 ± 24 0.5416 (ns) 
Diastolic BP 101 ± 10 129 ± 17 0.5208 (ns) 
 
The mean LDL-C among patients with Hemorrhagic 
transformation was 100 with a SD of 15 whereas, it was 113 with 
a SD of 17 for patients without hemorrhagic transformation. This 
carries a P value of 0.015 and is statistically significant. 
 
The mean Total cholesterol for patients with Hemorrhagic 
transformation was 177 with a SD of 17 and it was 188 with a SD 
of 17 among patients without Hemorrhagic transformation. This 
carries a P value of 0.0345 and is also statistically significant.  
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In contrast, the triglycerides, HDL-C and BP were almost same 
among the two groups with and without Hemorrhagic 
transformation and they carry no significant correlation. 
 
Other parameters in relation to Hemorrhagic transformation: 
 
AGE vs HEMORRHAGIC TRANSFORMATION  [P = 0.1790], not 
significant 
 Age <40 40-50 50-60 60-70 >70 
With HgT 3 2 4 5 1 
Without 
HgT 
0 6 17 8 4 
 
Again the incidence of large artery thrombotic stroke is more in 
the age group 50 – 60yrs. But there is no significant difference in 
the incidence of hemorrhagic transformation among various age 
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groups. The test carries a higher P value and is not statistically 
significant. 
 
SEX vs HEMORRHAGIC TRANSFORMATION  [P = 0.9119] not 
significant 
 Males Females 
Patients with HgT 10 5 
Patients without HgT 24 11 
 
The incidence of large artery infarct is higher among males and 
hence the incidence of hemorrhagic transformation. The test 
carries a higher P value and hence is not statistically significant. 
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ARTERIAL TERRITORY vs HEMORRHAGIC 
TRANSFORMATION  [ P = 0.3813 ] not siginificant 
 MCA territory PCA terittory ACA territory 
With HgT 12 3 0 
Without HgT 29 5 1 
 
MCA territory infarcts are more common and hence the incidence 
of hemorrhagic transformation. The test carries a higher P value 
and hence is not statistically significant. 
 
From the above data, it is clear that incidence of hemorrhagic 
transformation is in no way related to parameters like age, sex or 
the arterial territory involved. 
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CONCLUSION 
 
ICH mortality: 
 
1. It was found that LDL-C has no statistically significant 
relationship with ICH mortality in contrast to the studies 
performed by Ramirez Morino et al and Molina et al. 
2. Low total cholesterol to some extent predicts the mortality 
in ICH patients  
3. ICH volume has a very high significant correlation with the 
ICH mortality 
4. The other parameters like HDL-C, Triglycerides, age, sex and 
site of ICH have no significant correlation with mortality. 
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Hemorrhagic transformation: 
 
1. It was found that low LDL-C is directly related to the hemorrhagic 
transformation of large artery thrombotic infarct with a very low P 
value and is highly statistically significant. This supports the 
results found out by Kim et al. 
2. Similarly low Total cholesterol also is directly related to the 
incidence of hemorrhagic transformation. 
3. The other parameters like HDL-C, Triglycerides, blood pressure are 
not significantly related to Hemorrhagic transformation. 
4. Age, sex and the arterial territory involved also are not having any 
significant correlation with the incidence of hemorrhagic 
transformation. 
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Limitations of the study: 
 
1. The study population is comparatively less 
2. Exclusion criteria is broad 
3. Only people in and around Chennai were compared 
4. MRI detects hemorrhagic transformation better than CT and it is 
not used in this study due to economical reasons 
 
FURTHER STUDIES:  
 
The study has to be conducted in a larger population and the relation of 
LDL-C to the mortality in ICH patients should be established 
Since Low cholesterol patients are prone for hemorrhagic 
transformation, study has to be conducted whether thrombolysis can 
be done in patients with lower cholesterol. Clear role of statins in ICH 
patients and in patients with large artery infarct undergoing 
thrombolysis should be studied 
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                                         APPENDIX 
                                 ABBREVIATIONS 
ACA – Anterior Cerebral Artery 
ACEI – Angiotensin Converting Enzyme Inhibitors 
AHA – American Heart Association 
ASA – American Stroke Association 
ATP – Adenosine Triphosphate 
BBB – Blood Brain Barrier 
BP – Blood Pressure 
CBF – Cerebral Blood Flow 
CE – CardioEmbolism 
CPP – Cerebral Perfusion Pressure 
CT – Computed Tomography 
CTA – Computed Tomographic Angiography 
CVA – Cerebro Vascular Accident 
DWI – Diffusion Weighted Imaging 
EEG – ElectroEncephaloGram 
GCS – Glassgow Coma Scale 
HDL-C – High Density Lipoprotein Cholesterol 
HTf – Hemorrhagic Transformation 
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ICH – IntraCerebral Hemorrhage 
LAA – Large Artery Atherothrombosis 
LDL-C – Low density Lipoprotein Cholesterol 
MAP – Mean Arterial Pressure 
MCA – Middle Cerebral Artery 
MRI – Magnetic Resonance Imaging 
MRA – Magnetic Resonance Angiography 
NCCT – Non Contrast Computed Tomography 
ns – not statistically significant 
PCA – Posterior Cerebral Artery 
SD – Standard Deviation 
SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol 
Levels 
ss – statistically significant 
TC, Total C – Total Cholesterol 
TGL – Triglycerides 
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PROFORMA 
Proforma for Serum LDL-C and its relation to mortality in ICH pts, and risk of 
Hemorrhagic transformation in atherothrombotic stroke 
 
NAME:                                                                  AGE/SEX: 
 
OCCUPATION: 
 
ADDRESS AND CONTACT NUMBER: 
 
 
CLINICAL PRESENTATION: 
 
 
 
COMORBID ILLNESS: 
 
 
SMOKING: 
 
ALCOHOL: 
 
PREVIOUS HISTORY OF STROKE: 
 
 
PREVIOUS USE OF DRUGS: 
 
1. ANTIHYPERTENSIVES: 
 
2. ANTIDIABETICS: 
 
3. LIPID LOWERING AGENTS: 
 
4. ANTIPLATELETS AND ANTICOAGULANTS: 
 
                      
CLINICAL DIAGNOSIS: 
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GCS AT ADMISSION: 
 
BP AT ADMISSION: 
 
RBS AT ADMISSION: 
 
LIPID PROFILE AT ADMISSION: 
• TOTAL CHOLESTEROL: 
• HDL: 
• LDL: 
• TRIGLYCERIDES: 
 
PT/APTT: 
 
CT BRAIN AT THE TIME OF ADMISSION: 
 
 ISCHEMIA – LOCALISATION: 
 
 ICH: 
• LOCALISATION: 
 
 
• VOLUME: 
 
• VENTRICULAR EXTENSION: 
 
• INFRATENTORIAL AFFECTATION: 
 
FOUR VESSEL DOPPLER: 
 
 
 
 
 
CT BRAIN AT 1 WEEK OF ADMISSION: 
 
 
 
 
FOLLOW UP OF THE PATIENT UP TO 30 DAYS 
